Fixed-Ratio Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Treatment in Type 2 Diabetic (T2DM) Patients with Diabetic Foot Ulcers (DFU) and Critical Limb Ischemia (CLI)

被引：0
|
作者：
Falcetta, Pierpaolo
Indovina, Francesco S.
Giannarelli, Rosa
Piaggesi, Alberto
Penno, Giuseppe
Miccoli, Roberto
Del Prato, Stefano
Coppelli, Alberto
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2256-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2256-PUB
引用
收藏
页数：2
相关论文
共 33 条
  • [1] Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes
    Vedtofte, Louise
    Knop, Filip K.
    Vilsboll, Tina
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 387 - 396
  • [2] Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial
    Billings, L. K.
    Doshi, A.
    Gouet, D.
    Oviedo, A.
    Rodbard, H. W.
    Tentolouris, N.
    Gron, R.
    Halladin, N.
    Jodar, E.
    DIABETOLOGIA, 2017, 60 : S366 - S366
  • [3] Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients with Type 2 Diabetes (T2D): DUAL VII Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    DIABETES, 2017, 66 : A36 - A36
  • [4] Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
    Vilsboll, Tina
    Blevins, Thomas C.
    Jodar, Esteban
    Poulter, Neil
    Tentolouris, Nikolaos
    Agner, Bue F. Ross
    Lehmann, Lucine
    Leiter, Lawrence A.
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1506 - 1512
  • [5] Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial
    Jodar, E.
    Doshi, A.
    Gouet, D.
    Oviedo, A.
    Rodbard, H. W.
    Tentolouris, N.
    Busk, A. K.
    Basse, A.
    Billings, L. K.
    DIABETOLOGIA, 2017, 60 : S370 - S370
  • [6] Patient-Reported Outcomes (PROs) in Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients (Pts) with Type 2 Diabetes (T2D): DUAL VII Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Kirstine Busk, Anne
    Basse, Amaury
    Jodar, Esteban
    DIABETES, 2017, 66 : LB32 - LB32
  • [7] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM
    Kaneto, Hideaki
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Watanabe, Daisuke
    Niemoeller, Elisabeth
    DIABETES, 2019, 68
  • [8] The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting
    Drummond, Russell
    Malkin, Samuel
    Du Preez, Michelle
    Lee, Xin Ying
    Hunt, Barnaby
    DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2371 - 2378
  • [9] Stepwise Intensification of Prandial Insulin Versus Basal-Bolus Insulin Therapy in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)
    Raccah, Denis
    Haak, Thomas
    Huet, Dominique
    Monnier, Louis
    Penfornis, Alfred
    Robertson, Douglas
    Labard, Pascale
    Soler Ramon, Juan
    DIABETES, 2010, 59 : A151 - A151
  • [10] Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial
    Kaku, Kohei
    Araki, Eiichi
    Tanizawa, Yukio
    Agner, Bue Ross
    Nishida, Tomoyuki
    Ranthe, Mattis
    Inagaki, Nobuya
    DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2674 - 2683
1234